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Abstract
Phosphoinositide 3-kinases (PI3Ks) are important for synaptic plasticity and various brain functions. The only class IB
isoform of PI3K, PI3Kg, has received the most attention due to its unique roles in synaptic plasticity and cognition.
However, the potential role of PI3Kg in sensory transmission, such as pain and itch has not been examined. In this
study, we present the evidence for the first time, that genetic deletion of PI3Kg enhanced scratching behaviours in
histamine-dependent and protease-activated receptor 2 (PAR-2)-dependent itch. In contrast, PI3Kg-deficient mice
did not exhibit enhanced scratching in chloroquine-induced itch, suggesting that PI3Kg selectively contributes to
certain types of behavioal itch response. Furthermore, PI3Kg-deficient mice exhibited normal acute nociceptive
responses to thermal and mechanical noxious stimuli. Behavioral licking responses to intraplantar injections of
formalin and mechanical allodynia in a chronic inflammatory pain model (CFA) were also not affected by PI3Kg
gene deletion. Our findings indicate that PI3Kg selectively contributes to behavioral itching induced by histamine
and PAR-2 agonist, but not chloroquine agonist.
Introduction
PI3Ks are lipid kinases that phosphorylate the 3’-hydro-
xyl group of the inositol rings in phophatidylinositol
(PtdIns) substrates [1], and they also possess protein
kinase activity. PI3K signaling is well known for its mul-
tiple functions, including vesicle trafficking, cell metabo-
lism, and cell growth and survival [2]. PI3Ks are
classified as class I, class II, or class III based on sub-
strate binding and sequence homology; class I PI3Ks are
subdivided into a, b, g, and δ [2]. PI3Ks work as impor-
tant intracellular messengers, and may act downstream
of signaling proteins involved in the expression of long
term potentiation (LTP), or long term depression (LTD)
[3,4]. For example, PI3K antagonists block LTP expres-
sion in the CA1 region of the hippocampus [5]. More
recently, PI3K activity was shown to mediate stress-
induced impairments in hippocampal LTP and to facili-
tate stress-induced potentiation of hippocampal LTD in
adult rats [3]. Furthermore, previous observations
revealed that PI3K blockade prevents both AMPA and
NMDA receptor-mediated ERK1/2 activation [6]. Inter-
estingly, a recent genetic and pharmacological study
showed that PI3Kg is specifically involved in NMDA
receptor-dependent LTD and behavioural flexibility in
the hippocampus [7].
In addition to the hippocampus, PI3K has also been
reported in brain areas related to sensory transmission
and modulation. For example, PI3Kg has been found to
be expressed in cortical areas including the anterior cin-
gulate cortex (ACC), insular cortex and somatosensory
cortex [8]. In addition, various studies have identified
PI3K activity within the spinal cord [9,10]. Specifically,
PI3Kg has been detected in a subtype of C-fibers in dor-
sal root ganglion (DRG) neurons [11], and PI3Kg
expression in the dorsal horn of the spinal cord has
been reported (The Allen Mouse Brain Atlas). There-
fore, PI3Kg likely localizes with somatosensory pathways
and may contribute to sensory transmission, modulation
and plasticity. In accordance, activation of PI3K has
been reported in nociception [9,10,12]. Previous studies
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suggest that PI3K may activate downstream of key sig-
naling proteins involved in nociceptive sensitization,
such as nerve growth factor (NGF). For example, NGF
mediated TRPV1 receptor sensitization to capsaicin has
been found to be absent in mice lacking the PI3K regu-
latory subunit p85a [9]. Similarly, pharmacological
interventions have also revealed that PI3K inhibition can
attenuate GDNF mediated hyperalgesia [12]. Further-
more, PI3K activity was found to be significantly
increased in DRG neurons after spinal nerve injury, and
selective PI3K inhibition attenuated behavioral manifes-
tations of chronic pain [10]. Nevertheless, most of these
observations have employed pharmacological inhibitors
that are not selective for specific subtypes of PI3K.
Therefore, possible somatosensory contributions of
selective subtypes, such as PI3Kg have yet to be
investigated.
Itch is also a complex, unpleasant sensory experience
that plays an important role in protecting organisms
against potentially harmful agents [13]. Increasingly,
research into itch has begun to uncover its molecular
mechanisms, and it has become apparent that distinct
molecular substrates may exist for itch or pain, but
share some common signalling pathways (Table 1). For
example, superficial dorsal horn neurons in rats were
found to respond to both histamine and capsaicin sti-
mulation [14], (but see ref [15] for cat). Similarly, per-
ipheral serotonin stimulation has been shown to elicit
scratching behaviour and c-fos in lamina I-III neurons of
adult rats [16,17]. Correspondingly, several studies have
observed that histamine and other puritogens activate
superficial dorsal horn neurons in adult mice [13,18,19].
The gastrin releasing peptide (GRP) receptor (GRPR)
has emerged as a possible itch specific mediator at the
spinal cord [20]. Gene knockout mice lacking GRPRs,
display a significant reduction in scratching behavior in
response to peripheral application of histamine and
other pruritogens compared to wild type littermates, but
retain intact mechanical and thermal nociception. How-
ever, our recent studies found that glutamate, a key
excitatory transmitter for sensory nociceptive transmis-
sion, is also a key neurotransmitter for GRP-dependent
and -independent synaptic transmission in the mamma-
lian spinal cord [19]. Thus, it is likely that at the spinal
cord level, both pain and itch employ glutamate as a
common fast excitatory transmitter. It is thus unlikely
that there are selectively labeled sensory pathways or
transmitter for itch or pain.
Considering the role of PI3K and PI3Kg in synaptic
plasticity of glutamatergic synapses, we wanted to test if
subtypes of PI3K may preferentially contribute to itch.
In the present study, we investigated the behaviors of
PI3Kg knock-out mice to characterize the role of PI3Kg
in itch responses. We studied the effects of several prur-
itogens on PI3Kg knockout mice and identified several
itch-specific phenotypes with relatively intact pain
responses. We discovered that PI3Kg is an essential
molecule for histamine-dependent and protease-acti-
vated receptor 2 (PAR-2)-dependent itch behaviors, but
is not essential to chloroquine-dependent itch behaviors.
Methods
Animals
Male and female PI3Kg KO and WT littermates with a
C57BL/6J genetic background (back-crossings were exe-
cuted over 12 generations) were used for behavioral
experiments. We received PI3Kg mice initially from
Peter Backx, and backcrossed them to C57BL/6J more
than 15 times in our mouse facilities. All mice were
adults (8-12 weeks old) and housed under a 12:12 light
cycle with food and water provided ad libitum. The
Animal Care and Use Committee of Seoul National Uni-
versity approved all mouse protocols.
Nociceptive behavioral tests
All behavior experiments were performed under blind
conditions. The hot plate test was performed by placing
a mouse on a 48°C or 53°C hot plate (Harvard appara-
tus) and measuring the latency of hind limb response,
such as flinching, licking, and jumping. The maximum
Table 1 Recent itch studies using genetically engineered mice
Deleted gene Pruritogens Scratching Reference
PLCb3 Histamine, HTMT, Compound 48/80, Clobenpropit Reduced Neuron (2006)
GRPR Compound 48/80,
PAR-2, chloroquine
Reduced Nature (2007)
VGLUT2
(Spinal cord specific)
PAR-2, 5-HT, Chloroquine, Compound 48/80, Capsaicin Increased Neuron (2010)
Bhlhb5 Histamine, Compound 48/80
PAR-2, 5-HT, Chloroquine
Increased Neuron (2010)
TLR7 5-HT, ET-1, PAR-2,
Chloroquine
Reduced Nature Neuroscience (2010)
TRPA1 Chloroquine, BAM8-22 Reduced Nature Neuroscience (2011)
PI3Kg istamine, PAR-2 Increased The present study
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time allowed at 53°C was 30 seconds to prevent tissue
damage; if the animal did not respond within this time,
the animal was excluded.
Mechanical threshold was tested under non-restrained
conditions. Mice were allowed to acclimate to the ele-
vated wire mesh for 15 minutes before testing. A thresh-
old stimulus was determined by observing animal hind
paw withdrawal upon application of a von Frey filament
(Touch-Test kit, North Carolina, Inc.), and the threshold
was calculated with “up-and-down paradigm” [21]. Posi-
tive responses included prolonged hind paw withdrawal
and licking or biting of the hind paw. Mechanical allo-
dynia was tested on days 1, 3, and 7 after injection of
Complete Freund’s adjuvant (CFA, 10 μl, Sigma) into
the plantar of the right hind paw.
Formalin (5%, 10 μl) was injected as same as CFA.
The total time spent licking, flinching, and shaking the
injected area was recorded for each 5-minute interval
over 2 hours.
Itch behavioral tests
Itch behavior was recorded with a digital video camera
for 3-40 minutes. Each mouse was used only once, in
one experiment. All animals were habituated to the
observation chamber (200 × 260 × 130 mm) with proper
bedding for 30 minutes before testing. Pruritogens, his-
tamine (250 μg), PAR-2 agonist, SLIGRL-NH2 (100 μg),
and chloroquine (200 μg) were used. Each chemical was
injected intradermally into the nape of the neck via a
30-gauge Hamilton syringe in a volume of 20-25 μl.
One bout of scratching by either hind paw was defined
as a scratching episode. The scratching was quantified
as the total number of scratches plus the cumulative
number of scratches during 5-minute intervals over 3-
40 minute observation periods.
Pharmacological tests
The PI3Kg specific inhibitor, AS605240 (Calbiochem),
was dissolved in DMSO (Sigma) and the drug concen-
tration was adjusted with PBS. The total volume for
intraperitoneal injection was 200 μl from a 0.3-ml insu-
lin syringe (31-gauge). The inhibitor or vehicle was
injected intraperitoneally 30 minutes before behavioral
experiments, and the mice were allowed to adapt to the
testing cage immediately following injection.
Data Analysis
Results are presented as the mean ± standard error of
the mean (s.e.m.). Statistical comparisons were per-
formed by one- or two-way analysis of variance
(ANOVA). For the total number of itch behaviours and
basal mechanical thresholds, unpaired Student’s t-test
was used. In all cases p < 0.05 was considered statisti-
cally significant.
Results
Acute nociception
To investigate PI3Kg involvement in acute nociception,
we measured basal thermal and mechanical sensitivity in
PI3Kg knockout (KO) mice and wild-type (WT) litter-
mates. The hot-plate (HP) test showed similar paw with-
drawal latencies at 48°C and 53°C in both groups (HP at
48°C, WT = 50.6 ± 5.2 sec, KO = 49.2 ± 4.7 sec; HP at
53°C, WT = 19.6 ± 2.0 sec, KO = 21.6 ± 1.4 sec; WT n
= 10, KO n = 7; two-way ANOVA, genotype factor, p >
0.05, Figure 1A). Next, we measured behavioural
responses to mechanical stimuli. No significant differ-
ences in the withdrawal response were observed
between PI3Kg KO and WT mice (WT = 0.46 ± 0.18 g,
KO = 0.34 ± 0.12 g; n = 7 for each group; unpaired t-
test, p > 0.05, Figure 1B). Taken together, these results
suggest that PI3Kg does not contribute to acute nocicep-
tion in mice.
Normal range of nociception to chemical inflammation
Considering the important roles of PI3K on synaptic
plasticity, we then examined the responses of PI3Kg
KO and WT to more prolonged nociceptive stimulus,
peripheral formalin injection. Formalin is a common
model for tissue injury and inflammation [21]. To test
formalin-induced pain, intraplantar injection (5%, 10
μl) was made in the right side of the hind paw. As we
reported before [21], mice responded by licking the
injected hindpaw, and this behaviour is typically con-
centrated in three distinct phases: a first phase (0-10
min), a second phase (10-55 min) and a third phase
(55-120 min). We thus recorded their pain response
for 2 hours after formalin injection to observe any
long-term effects of sensitization. We found that there
were no significant differences in response to formalin
between the groups (WT n = 6, KO n = 9; two-way
repeated measures ANOVA, genotype factor, p > 0.05,
Figure 2A). Interestingly, the formalin graph shows a
slight trend towards an increased pain response in
PI3Kg KO mice during the phase 3, but the mean dif-
ference was not statistically significant (WT = 165.9 ±
35.6 sec, KO = 262.3 ± 51.9 sec; unpaired t-test, p >
0.05, Figure 2A-B).
Next, CFA was used to study chronic inflammatory
pain behaviour as we have previously examined. Beha-
vioural allodynia was measured 1, 3, and 7 days after the
intraplantar CFA injection. Both PI3Kg KO and their
WT littermates displayed similar levels of hyper
mechanical sensitivity to a series of von Frey filaments.
No significant differences were observed in the reduced
mechanical threshold (n = 7 for each group; two-way
ANOVA, genotype factor, p > 0.05, Figure 2C). These
results suggest that PI3Kg activity is not required for
behaviroal responses to inflammatory injury.
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Figure 1 Intact acute nociception in PI3Kg-deficient mice. (A) Hot plate test results show that PI3Kg KO and WT littermates have similar
behavioral responses to thermal stimuli. (B) Basal mechanical threshold was measured and no significant differences were detected between the
groups.
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Figure 2 Intact chemical-induced pain in PI3Kg-deficient mice. (A and B) Formalin-induced inflammatory pain response indicates that PI3Kg
KO and WT littermates have no significant nociceptive differences. (C) CFA-induced allodynia was measured 1, 3, and 7 days after the injection,
and no significant differences were observed in hypersensitivity to mechanical touch.
Lee et al. Molecular Pain 2011, 7:96
http://www.molecularpain.com/content/7/1/96
Page 5 of 11
Abnormal scratching behaviour induced by histamine and
PAR-2 agonist
Histamine is well-known pruritogen that induces
scratching behaviour, and it has been used to identify
itch receptors in the human skin [22]. Recently, rodent
model has been developed to satisfy clinical needs in the
field of itch and enabled genetic studies [23]. To exam-
ine if the loss of PI3Kg affects behavioural itch, we con-
ducted initial experiments with histamine. Scratching
behaviour was recorded for 40 minutes, and the number
of scratches was counted in a blind manner. We
observed itch behaviour for 40 minutes because most of
the mice barely scratched after then. As previously
reported [24], all mice started scratching behaviour after
the intradermal injection of histamine. Surprisingly, the
scratching in PI3Kg KO mice was significantly enhanced
overall. As a result, the total number of scratches for 40
minutes was significantly higher in the PI3Kg KO group
compared to their WT littermates (total number of
scratches, WT = 68.8 ± 9.5, KO = 117.2 ± 13.3; n = 10
for each group; unpaired t-test, p < 0.01; number of
scratches, two-way repeated measures ANOVA, geno-
type factor, p < 0.001, Figure 3A-B).
Other well-known pruritogen proteases were chosen
to study if histamine-independent signaling is also
related to PI3Kg deficiency. A recent study showed that
agonists of protease-activated receptor 2 (PAR2) induce
itch [25]. We performed another set of itch experiments
with the PAR-2 agonist, SLIGRL-NH2 and observed
scratching behavior for 30 minutes. In consistent with
the previous results, both WT and KO mice exhibited
increased scratching behavior triggered by the PAR-2
agonist injection. Interestingly, PI3Kg KO mice exhibited
vigorous scratches compared to the WT group (total
number of scratches, WT = 171.2 ± 26.2, KO = 308.7 ±
41.3; unpaired t-test, p <0.05; number of scratches, two-
way repeated measures ANOVA, genotype factor, p <
0.05, Figure 3C-D). PI3Kg KO mice particularly dis-
played hyper scratching during the first 5 minutes, and
the mean difference between the groups during the first
5 minutes was significantly different (scratches during
the first 5 minutes, WT = 27.7 ± 7.1, KO = 70.9 ± 8.1;
unpaired t-test, p < 0.01, Figure 3E). Additionally, PI3Kg
KO mice displayed significantly shorter scratching laten-
cies than WT littermates, which were followed by con-
sistent, vigorous scratching behaviour throughout the
experiment (WT = 185.8 ± 24.4, KO = 39.1 ± 4.9;
unpaired t-test, p < 0.001, Figure 3F). The reason that
this early onset of scratch in PAR-2 dependent itch is
interesting is because no differences were detected in
scratching latencies in response to the histamine appli-
cation. Therefore, PAR-2 dependent itch implies a
unique mechanism with PI3Kg and suggests a pivotal
role of PI3Kg in protease-mediated itch.
Normal scratching in chloroquine-induced itch
Chloroquine is a widely used antimalarial medication,
but it has a serious side effect that patients often have
itch. A recent study investigated chloroquine-mediated
itch pathway in mice [26], and chloroquine was found
to bind sensory neuron-specific GPCR Mrgprs. In addi-
tion, another study showed that TRPA1 is required to
itch response induced by chloroquine [27]. To charac-
terize PI3Kg in the function of itch, we used chloroquine
as another type of histamine-independent itch model.
Chloroquine was injected intradermally and subsequent
behavioral scratching responses were recorded in the
same fashion as the above experiments. Unlike previous
results with histamine and PAR-2 agonism, chloroquine-
induced itch did not trigger hyper scratching behavior
in PI3Kg KO mice compared to WT littermates (WT =
110.3 ± 17.0, KO = 163.1 ± 48.5; unpaired t-test, p >
0.05, Figure 4A; two-way repeated measures ANOVA,
genotype factor, p > 0.05, Figure 4B). This negative
result implies that the chloroquine receptors may reside
in the sensory transmission pathway irrespective of
PI3Kg. Overall, the absence of PI3Kg did not affect
chloroquine-induced scratching.
Pharmacological inhibition of PI3Kg
To investigate if acute pharmacological inhibition of
PI3Kg in naïve mice results in enhanced scratching, we
treated naïve mice with the PI3Kg-specific inhibitor,
AS605240 [28], and conducted an itch experiment with
histamine. Adult naïve mice were injected intraperitone-
ally with either inhibitor or vehicle. The pharmacologi-
cal inhibition of PI3Kg prior to the itch test did not lead
to significantly enhanced scratches (n = 12 for each
group; one-way ANOVA, p >0.05, Figure 5A-B). Since
the experiments for the higher dose group (50 μg) and
the vehicle group were conducted simultaneously, we
were able to analyze the difference in the number of
scratches between the two groups. The number of
scratches appeared to be higher in the higher dose
group (50 μg) compared to the vehicle group, but the
numbers did not reach statistical significance (vehicle =
110.7 ± 11.9, 50 μg of drug = 136.6 ± 8.2; unpaired t-
test, p = 0.08, Figure 5A). One possible difference
between results of PI3Kg KO mice and the PI3Kg inhibi-
tor is that pharmacological inhibition is not complete or
specific. Future studies are clearly needed when more
selective inhibitors become available.
Discussion
This is the first study identifying PI3Kg as a mediator of
itch sensation in the mammalian system. We report that
PI3Kg-deficient mice exhibit enhanced scratching in
response to intradermal injections of histamine and
PAR-2 agonists compared to WT littermates.
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Furthermore, PI3Kg-deficient mice demonstrated signifi-
cantly shorter latencies for scratching and much more
pronounced scratching behaviors in response to PAR-2
agonist treatment. In contrast, acute mechanical and
thermal thresholds were unaltered by PI3Kg deletion,
and chemical-induced pain responses resembled that of
WT littermates. Surprisingly, enhanced scratching was
not observed in PI3Kg KO mice during the chloroquine-
Figure 3 Histamine and PAR-2-induced hyper scratching in PI3Kg deficient mice. (A and B) The total number of scratches that occurred
over a 40-minute time period after histamine injection were counted. PI3Kg KO exhibited enhanced scratching compared to WT littermates. (C
and D) PAR-2 agonist induced itch was recorded; scratches were counted for 30 minutes. (E and F) The PI3Kg KO scratched vigorously for the
first 5 minutes; the latency until the first scratch was significantly earlier than in WT mice.
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induced itch experiments, suggesting a distinct intracel-
lular mechanism for this form of itch behavior.
Spinal PI3K, pain and itch
Pain and itch mechanisms have long been suspected to
overlap. Mounting evidence suggests that C-fibre inner-
vation provides pruritogenic transmission, and we have
previously shown that GRP sensitive neurons almost
exclusively receive primary afferent C-fiber input;
whereas GRP insensitive neurons mostly received Aδ
fiber input. However, electrophysiological studies
revealed that sensory transmission in both GRP-sensitive
or insensitive neurons receive glutamatergic innerva-
tions. These findings suggest that GRP is not a selective
transmitter for itch as originally proposed [20]. This
notion is further supported by the observation that itch
and pain transmission can be modulated through
TRPV1-expressing primary afferents [22]. Histamine
induced activation was shown to be TRPV1 dependent
in mouse primary afferent neurons [23]. In accordance,
Figure 4 Similar scratch levels in chloroquine-induced itch. (A) No significant differences were observed in the number of scratches found in
chloroquine-induced itch experiments with PI3Kg KO and WT littermates. (B) Enhanced itch behaviors following chloroquine injection were not
observed during the 30-minute time period following injection.
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NGF mediated TRPV1 channel sensitization to capsaicin
is sensitive to disruptions in PI3K levels [9]. Similarly, a
histamine-independent pruritogen, protease-activated
receptor 2 agonist (PAR-2), is another well-known itch
inducer and has been reported to sensitize TRPV1 chan-
nels to induce hyperalgesia in small-to-medium dia-
meter neurons of the DRG [24]. Thus it is possible that
PI3Kg may contribute to itch-related sensitization at
peripheral sites.
Much research has presented evidence of central sen-
sitization in chronic pain [25,26] and chronic itch [13].
Chronic pain has been found to manifest through sus-
tained potentiation of nociceptive systems. PI3K activity
was found to significantly increase in DRG neurons in
response to spinal nerve injury, and selective PI3K inhi-
bition successfully attenuated behavioral manifestations
of chronic pain [10]. Therefore, it is possible that PI3Kg
may mediate its effects by affecting glutamate release
mechanisms. Indeed, several lines of evidence suggest a
role for glutamate transmission in itch sensation [12,19].
VGLUT2 deficient mice show robust itch phenotypes,
whereby scratching behaviour becomes so pronounced
that tissue damage develops [10]. More recently, we
showed that C-fiber evoked responses in GRP sensitive
neurons within the dorsal horn were sensitive to CNQX
[19]. In contrast, VGLUT2-dependent glutamate release
Figure 5 Acute pharmacological inhibition of PI3Kg and histamine-dependent itch test. (A-B) Intraperitoneal injection of PI3Kg selective
inhibitor, AS605240, prior to an itch experiment did not induce significantly enhanced scratches in the drug group compared to the vehicle
group.
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from DRG neurons has been reported to suppress itch
[27].
Cortical and subcortical contributions
PI3Kg is expressed in the cortex [8], and has been impli-
cated in synaptic plasticity related events within the hip-
pocampus. The robust potentiation of itch behaviour in
PI3Kg KO mice could be explained through a reduction
of excitatory input to inhibitory neurons. In the ACC,
GRP has been shown to increase the frequency of
sIPSCs [28], and it would be of interest to see if PI3Kg
mediates this facilitation. The implication that PI3Kg
may mediate glutamatergic transmission corresponds
well with previous observations that PI3K activity is cri-
tical for AMPA receptor insertion in hippocampal LTP
[29]. More recently, it was observed that PI3K inhibition
attenuates Ca2+-permeable AMPA receptor mediated
LTP at CA1 hippocampal synapses in adult mice [30].
Furthermore, stress was observed to induce hippocam-
pal PI3K activity that corresponded with both an
attenuation of LTP and facilitation of LTD, whereas
intra-hippocampal injections of the PI3K inhibitor
LY294002 blocked these effects [3]. Therefore, PI3Kg
could mediate pruritogenic mechanisms through the
regulation of inhibitory neuronal activity, whereby a
reduction of PI3Kg prevents AMPA receptor driven
GABAergic neuronal activity.
Functional implications
Chronic pruritus is a debilitating condition that is
poorly understood. Recent reports suggest that the N-
methyl-D-aspartate (NMDA) glutamate receptor may be
a therapeutic target for the treatment of itch, but
although effective, it is greatly hampered by the numer-
ous undesirable side effects to the central nervous sys-
tem [31]. Thus P13Kg may present a novel
pharmacological target to modulate itch specific
responses through targeting pruritogenic receptor
mediated alterations in glutamatergic transmission.
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